Latest Breaking News On - Resminostat kinselby - Page 1 : comparemela.com

4SC: Landmark RESMAIN study data presented at the 5th World Congress of Cutaneous Lymphomas

Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice.Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company.

United statesResminostat kinselbyRudolf stadlerYakult honshaJason loveridgeWorld congressStandard of the frankfurt stock exchangeUniversity hospital johannes weslingCutaneoust cell lymphomaCutaneous lymphomasMarketing authorizationEuropean unionPrime standardFrankfurt stock exchange

Lymphoma maintenance therapy delivers promise in CTCL

Lymphoma maintenance therapy delivers promise in CTCL
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United kingdomNoord hollandResminostat kinselbyJason loveridgeCutaneous lymphoma tumour group annual meetingLeiden university medical center amsterdamLymphoma tumour group annual meetingLeiden university medical center